Shingrix vaccine and GLP-1 drug to preserve pancreas function in new type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether a shingles vaccine (Shingrix) combined with a diabetes medication (a GLP-1 agonist) can help preserve your pancreas's ability to make insulin when you've recently been diagnosed with type 1 diabetes. The goal is to slow down the autoimmune attack on your insulin-producing cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Recently diagnosed with type 1 diabetes (within 100 days of starting insulin)
- Age 18–50 years old
- Still have some pancreas function (shown by a blood test called C-peptide level)
- Have specific diabetes-related antibodies in your blood (a sign of autoimmune type 1 diabetes)
- Able and willing to check blood sugar multiple times daily and take insulin as directed
- Not pregnant, not breastfeeding, and willing to use effective birth control if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (rezpegaldesleukin) to see if it can help preserve the body's ability to make some insulin in people recently diagnosed with type 1 diabetes. It's for children and adults diagnosed within the past 100 days.
This early-stage trial tests a combination approach to help your immune system stop attacking insulin-producing cells in newly diagnosed type 1 diabetes. It aims to preserve your body's ability to make insulin and slow disease progression.
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
This study tests two different medicines (empagliflozin or semaglutide) added to your usual insulin to see if they help with blood sugar control and weight loss in people with type 1 diabetes who are overweight or have obesity. It may be a good fit if your diabetes is not well controlled with insulin injections alone.
This trial tests a medicine called a GLP-1 receptor agonist (like Ozempic) to see if it can help people with very early type 1 diabetes (stage 1) keep their insulin-making cells working longer. You may be a good fit if you have stage 1 type 1 diabetes and haven't needed insulin yet.
This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.